The regulator - the US Food and Drug Administration - said its decision was a "historic" moment and medicine was now "entering a new frontier".
The company Novartis is charging Rs66,003,509.51 ($475,000) (Rs65,566,240.09 (£367,000)) for the "living drug" therapy, which leaves 83% of people free...